We report net peptide content, not just purity — so the milligrams you dose aren't padded with water and counter-ion. RP-HPLC purity and ESI-MS identity, on a lot-numbered COA.
Net peptide content, not just purity — RP-HPLC + ESI-MS, lot-numbered COA.
Net peptide content on every lot's COA.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Angiotensin IV-derived peptidomimetic; synaptogenesis reference
Overview
Dihexa is a synthetic angiotensin-IV-derived oligopeptide (N-hexanoyl-Tyr-Ile-(6)-aminohexanoic acid amide) engineered as a blood-brain-barrier-penetrant research tool for synaptogenesis and neurotrophic studies; its lipophilic N-hexanoyl cap places it at the peptide/small-molecule boundary. In laboratory models it is studied as a reported inducer of dendritic-spine and synapse formation acting through hepatocyte growth factor (HGF)/c-Met signaling. Lyochem supplies Dihexa as a lyophilized reference standard at ≥99.0% HPLC. Because the acyl modification dominates its chromatographic behaviour, the release packet centres on reversed-phase HPLC with ESI-MS intact-mass confirmation against the 504.7 Da target and LC-MS/MS to localise the hexanoyl cap; residual-solvent and water-content data accompany each lot.
Applications & buyer fit
Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the published literature is intranasal — Semax, Selank, DSIP, Pinealon — because these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the CoA stage so the bioassay readout is not confounded by contamination unrelated to the test article.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Biotech R&D Groups
Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
Made available by Lyochem for laboratory research and analytical reference use only; it is not intended for human or animal use or for any clinical purpose.
Selected literature
Frequently asked questions
Reversed-phase HPLC establishes main-peak purity (≥99.0%), ESI intact-mass spectrometry confirms the 504.7 Da modified mass, and LC-MS/MS fragmentation localises the N-hexanoyl cap and aminohexanoic spacer that distinguish Dihexa from an uncapped angiotensin-IV fragment. Residual-solvent and Karl Fischer water content are reported per lot.
The lipophilic hexanoyl group makes Dihexa poorly soluble in plain aqueous buffer; prepare a concentrated stock in a research-grade organic co-solvent first, then dilute into buffer immediately before use, keeping the final co-solvent fraction low. Store the concentrated stock frozen and desiccated.